

Discussion Questions

- What are the potential uses of these types of predictive approaches to heterogeneity of treatment effect in terms of FDA processes? ?Labeling changes? ?Drug snapshots? Other?
- Are there priority areas for the FDA where these types of analyses might be most informative?
- What are potential caveats/limitations/concerns with these approaches from a regulatory perspective?

Peter Stein, MD
FDA, CDER